Influence of medicinal cannabis (Bedrocan) on the pharmacokinetics of irinotecan and docetaxel in cancer patients
| ISRCTN | ISRCTN72088851 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN72088851 |
| Secondary identifying numbers | METC 2003-171 Erasmus MC, NL772, NTR783 |
- Submission date
- 28/12/2006
- Registration date
- 28/12/2006
- Last edited
- 06/01/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Not provided at time of registration
Contact information
Dr F A de Jong
Scientific
Scientific
Erasmus MC Daniel den Hoed Kliniek
Groene Hilledijk 301
Rotterdam
3075 EA
Netherlands
| f.a.dejong@erasmusmc.nl |
Study information
| Study design | Crossover trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Single-centre |
| Study setting(s) | Not specified |
| Study type | Treatment |
| Scientific title | Influence of medicinal cannabis (Bedrocan) on the pharmacokinetics of irinotecan and docetaxel in cancer patients |
| Study hypothesis | To determine the influence of oral medicinal cannabis on the pharmacokinetics of irinotecan and docetaxel and their respective metabolites in cancer patients. |
| Ethics approval(s) | Ethics approval received from the local medical ethics committee |
| Condition | Cancer |
| Intervention | Course 1 irinotecan: patients will be treated with 600 mg irinotecan given as a 90-minute intravenous infusion in 250 ml NaCl 0.9% (t = 0, day one, course 1). Course 1 docetaxel: patients will be treated with 180 mg docetaxel given as one-hour intravenous infusion in 250 ml NaCl 0.9% (t = 0, day one, course 1). As an (extra) safety assessment, pharmacokinetic profiles will be determined before day seven of course 1. Only patients who do not develop abnormal toxicity or an abnormal pharmacokinetic profile and for whom no dose reduction due to an increased risk for toxicity would have been necessary (if a second course of irinotecan or docetaxel without cannabis were to be given), will be further treated according to the study protocol. The decision to further treat a patient according to the study protocol will be made by the responsible physician and the study coordinators and will take prior to the start of the medicinal cannabis treatment). Patients who remain included in the study will receive medicinal cannabis during 15 days, starting on day ten, course 1. On day one, course 2 (i.e. day 22) the second course of docetaxel or irinotecan will be given. The last three days of medicinal cannabis will thus be given during the second course of chemotherapy (i.e. day one to three, course 2). Course 2 irinotecan: patients will be treated with 450 mg irinotecan given as a 90-minute intravenous infusion in 250 ml NaCl 0.9% (t = 0, day one, course 2). Course 2 docetaxel: patients will be treated with 135 mg docetaxel given as one-hour intravenous infusion in 250 ml NaCl 0.9% (t = 0, day one, course 2). For safety reasons, a 25% dose reduction will be applied during the combination therapy in at least the first three irinotecan and the first three docetaxel patients. A safety evaluation will be performed after these first three patients in each chemotherapy arm have been treated to evaluate safety (i.e. toxicity). Based upon this evaluation, the chosen dose reduction of 25% will be re-adjusted or maintained. Not before this safety (i.e. pharmacokinetic/pharmacodynamic) evaluation has been performed, will the study be continued. Medicinal cannabis treatment: patients will receive a standardised dose of once daily (in the evening) 200 ml medicinal cannabis tea (1g/L). This is the recommended therapeutical dose of orally administered medicinal cannabis (oral information Bureau for Medicinal Cannabis [BMC]: Mr. Scholten; http://www.maripharm.nl). The tea will be brewed using a standardised medicinal cannabis extract, Bedrocan, which is standardised at 21.8% delta-9-TetraHydroCannabinoid (THC), 189 mg/100 g CannaBiDiol (CBD) and 3.2 mg/100g CannaBiNol (CBN). The medicinal cannabis extract (Bedrocan) is produced by BMC-licensed and approved cultivators according to Good Manufacturing Practice (GMP) and will be purchased from the BMC. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Bedrocan, irinotecan and docetaxel |
| Primary outcome measure | 1. Irinotecan and metabolite pharmacokinetics, course 1 and 2 2. Docetaxel pharmacokinetics, course 1 and 2 |
| Secondary outcome measures | Haematological toxicity course 1 and 2 |
| Overall study start date | 01/01/2004 |
| Overall study end date | 01/01/2006 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Not Specified |
| Target number of participants | 24 |
| Total final enrolment | 24 |
| Participant inclusion criteria | 1. Histological or cytological confirmed diagnosis of any form of (metastatic) cancer: a. which is refractory to conventional treatment; or b. for which no other (effective) treatment options are available 2. Age 18 years and older 3. World Health Organisation (WHO) performance grade two or less 4. Adequate hematological functions (absolute neutrophil count more than 2.0 x 10^9/L, platelets more than 100 x 10^9/L) 5. Adequate renal and hepatic functions: bilirubin less than 1.25 x Upper Limit of Normal (ULN); Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT) less than 2.5 x ULN, in case of liver metastasis less than 5 x ULN; serum creatinine less than 1.25 x ULN; Alkaline Phosphatase (AP) 5 x ULN; patients with SGPT and/or SGOT more than 1.5 x ULN associated with AP more than 2.5 x ULN are not eligible for the docetaxel arm 6. Written informed consent 7. Complete initial work-up within two weeks prior to chemotherapy 8. Willingness to abstain from grapefruit, grapefruit juice, herbal dietary supplements, and herbal tea during the study period (starting three weeks before the first course) 9. Willingness to abstain from alcohol, car-driving, use of dangerous instruments and machinery or engagement in hazardous activity during the time of medicinal cannabis-use because of (non-excludable) interference with logical thinking, ability to concentrate, and response speed |
| Participant exclusion criteria | 1. Pregnant or lactating patients; patients with reproductive potential must use a reliable method of contraception (excluding oral contraceptives), if required 2. Symptomatic Central Nervous System (CNS) metastases 3. Other serious illness or medical unstable condition requiring treatment or history of psychiatric disorder that would prohibit the understanding and giving of informed consent 4. Time between last anti-tumor chemotherapy treatment and first day of irinotecan or docetaxel therapy less than four weeks, provided that the patient has recovered from all relevant toxic effects 5. Radiotherapy within the last four weeks before chemotherapy, unless less than 20% of the bone marrow area is involved 6. Major surgery within four weeks before study entry (to be determined by a Medical Doctor) 7. History of alcohol or drug abuse, including current substance dependence, methadone maintenance 8. Use of St John's wort and/or other herbal medicines within four weeks before study entry 9. Current cannabis use and/or history of marijuana/cannabis abuse 10. (Chronic) use of CYP3A inhibiting medication, dietary supplements or other inhibiting compounds 11. (Chronic) use of CYP3A inducing medication, dietary supplements or other inducing compounds 12. Unwillingness to change medication, or no adequate alternatives available, when drugs known to interact with CYP3A isozymes, are taken 13. History of serious depression, schizophrenia, or psychosis Additionally for irinotecan patients: 1. Unresolved bowel obstruction or chronic colic disease 2. Radiotherapy at abdomen |
| Recruitment start date | 01/01/2004 |
| Recruitment end date | 01/01/2006 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Erasmus MC Daniel den Hoed Kliniek
Rotterdam
3075 EA
Netherlands
3075 EA
Netherlands
Sponsor information
Erasmus Medical Centre (The Netherlands)
Hospital/treatment centre
Hospital/treatment centre
Daniel den Hoed Kliniek
afdeling Interne Oncologie
Postbus 5201
Rotterdam
3008 AE
Netherlands
| Website | http://www.erasmusmc.nl/#http://www.erasmusmc.nl/ |
|---|---|
"ROR" |
https://ror.org/018906e22 |
Funders
Funder type
Hospital/treatment centre
Erasmus Medical Centre (The Netherlands)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/03/2007 | 06/01/2021 | Yes | No |
Editorial Notes
06/01/2021: The following changes have been made:
1. Publication reference added.
2. The final enrolment number has been added from the reference.
3. The NTR numbers have been added.
